Nevia Bio Ltd. (formerly Gina Life Ltd.) completed a $3.1 million seed round that will allow the company, which has developed a platform that can decode biomarkers data from vaginal secretions for the early detection of ovarian cancer, to conduct clinical trials. With ovarian cancer the leading cause of death in women diagnosed with gynecological cancers, Nevia is hoping that its platform will save many lives.
Manhattan Scientifics Inc. , which provided the initial funding &, currently owns more than 50 million shares of Imagion Biosystems Ltd. celebrates Imagion s remarkable progress in early cancer. | May 31, 2023
Global Cancer Technology is developing innovative treatments for deadly diseases like cancer, with a current focus on glioblastoma and breast cancer. To.
The S&P/ASX200 index gained 1.05% today on lower than normal volume, with 9 of 11 sectors higher. Information Technology led the winners, gaining 3.55%.